- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
Patent holdings for IPC class A61K 31/505
Total number of patents in this class: 5246
10-year publication summary
|
340
|
321
|
348
|
347
|
367
|
300
|
308
|
311
|
308
|
163
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Novartis AG | 10178 |
85 |
| Merck Sharp & Dohme LLC | 3736 |
82 |
| Bristol-myers Squibb Company | 4748 |
74 |
| Janssen Sciences Ireland Unlimited Company | 375 |
54 |
| Boehringer Ingelheim International GmbH | 4483 |
50 |
| Acetylon Pharmaceuticals, Inc. | 67 |
44 |
| Rigel Pharmaceuticals, Inc. | 505 |
44 |
| AstraZeneca AB | 2824 |
43 |
| Merck Sharp & Dohme Corp. | 2183 |
41 |
| Janssen Pharmaceutica N.V. | 3161 |
41 |
| Amarin Pharmaceuticals Ireland Limited | 271 |
41 |
| Abbvie Inc. | 1822 |
36 |
| Takeda Pharmaceutical Company Limited | 2712 |
36 |
| The Regents of the University of California | 20802 |
32 |
| Dana-Farber Cancer Institute, Inc. | 2668 |
31 |
| ViiV Healthcare Company | 164 |
31 |
| F. Hoffmann-La Roche AG | 7815 |
28 |
| Signal Pharmaceuticals, LLC | 176 |
25 |
| Amgen Inc. | 4436 |
24 |
| Merck Patent GmbH | 5735 |
23 |
| Other owners | 4381 |